NVCR - NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript
2024-05-02 11:43:08 ET
NovoCure Limited (NVCR)
Q1 2024 Earnings Conference Call
May 02, 2024 08:00 AM ET
Company Participants
Ingrid Goldberg - Investor Relations
Bill Doyle - Executive Chairman
Asaf Danziger - Chief Executive Officer
Ashley Cordova - Chief Financial Officer
Frank Leonard - Executive VP and President of NovoCure Oncology
Nicolas Leupin - Chief Medical Officer
Conference Call Participants
Jason Bednar - Piper Sandler
Jonathan Chang - Leerink Partners
Jessica Fye - J.P. Morgan Chase
Emily Bodnar - H.C. Wainwright
Presentation
Operator
Good day and thank you for standing by. Welcome to the NovoCure Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Ingrid Goldberg.
Ingrid Goldberg
Good morning, and thank you for joining us to review NovoCure's first quarter 2024 performance. I am joined this morning by our Executive Chairman, Bill Doyle; our CEO, Asaf Danziger; and our CFO, Ashley Cordova. Other members of our executive leadership team will be available for Q&A. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com and on our Investor Relations page under Quarterly Reports.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement, except as required by law....
NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript